doi: 10.3389/fendo.2025.1572997 Received 08 February 2025 Accepted 25 June 2025 Published 10 July 2025 Volume 16 - 2025 Edited by Terry Francis Davies, Icahn School of Medicine at Mount Sinai, United States Reviewed by Morteza Gholami, Golestan University, Iran Lucia Acampora, University of Naples Federico II, Italy Updates Copyright 2025 Cui, Wang, Li, Liu, Wang and Zhao
preparing to launch its Phase 2b Plateau study in Q1 2026, testing whether enobosarm, a selective androgen receptor modulator, can enhance GLP-1driven weight loss by preserving lean mass
Read the press release: This designation highlights the potential of NPI-001 to address a significant unmet need and represents an important step toward providing a new treatment option for patients living with #VisionLoss caused by RP
SynaPep BPC-157 is an advanced oral peptide therapy designed to support tissue repair, calm persistent inflammation, and promote more efficient recovery